Cartesian Therapeutics, Inc.
HealthcareNASDAQ:RNAC · NASDAQ Global Market
+$1.45 today
Vol 0.88M · Avg 0.23M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
103.2%
avg 179.4%
ROIC
-28.4%
avg -54.0%
ROA
-44.0%
avg -48.8%
Analysis
ROE is currently the strongest return metric at 103.2% versus its period average of 179.4%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Peter G. Traber | Head of R&D | $2.76M | — | 71 | — | — |
Carsten Brunn | President, Chief Executive Officer & Chairman of the Board | $1.04M | — | 55 | $323,530.00 | 1.10% |
Metin Kurtoglu | Consultant | $713,661.00 | — | 47 | $62,258.00 | 0.21% |
Blaine T. Davis | Chief Financial Officer | $693,345.00 | — | 52 | $121,220.00 | 0.41% |
Emily English | Chief Operating Officer | $589,814.00 | — | 46 | $94,226.00 | 0.32% |
Milos Miljkovic | Chief Medical Officer | $569,443.00 | — | 42 | $58,820.00 | 0.20% |
Matthew Bartholomae | General Counsel & Secretary | — | — | — | — | — |
June Seymour | Chief Accounting Officer | — | — | 48 | $19,000.00 | 0.06% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$205,797.00
Sells
3
$258,671.22
Net Sentiment
$52,874.22
Net selling
Most Active
Brunn Carsten
1 transactions
Analysis
Insiders reported 1 buys worth $205,797.00 and 3 sells worth $258,671.22 over the last 12 months. That adds up to net selling of $52,874.22. Brunn Carsten was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -46.8% | +58.4% (12yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -46.8% over three years. Forward estimates point to Revenue at +58.4% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Genfit S.A.
GNFT
$445.68M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
$284.66M
Fennec Pharmaceuticals Inc.
NASDAQ:FENC
$257.22M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$245.51M
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
$202.22M
Inventiva S.A.
NASDAQ:IVA
$200.13M
Avalo Therapeutics, Inc.
NASDAQ:AVTX
$166.70M
MediWound Ltd.
NASDAQ:MDWD
$154.46M
Neonc Technologies Holdings, Inc.
NASDAQ:NTHI
$94.98M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
$85.08M
Who manages RNAC?
Cartesian Therapeutics, Inc. (RNAC) lists 8 active executives. The top listed executive is Blaine T. Davis, Chief Financial Officer.
Are RNAC insiders buying or selling?
Recent insider activity shows net buying of $72.36M.
Explore More
Continue the stock analysis
Jump to another research area for this company.